We are live on
!
Find out more
BGI
B Group Inc Portfolio holdings
AUM
$135M
1-Year Est. Return
80%
This Fund
S&P 500
This Quarter
Est. Return
-16.75%
1 Year Est. Return
+80%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$135M
AUM Growth
-$547K
(-0.4%)
Cap. Flow
+$39.5M
Cap. Flow
% of AUM
29.27%
Top 10 Holdings %
Top 10 Hldgs %
81.07%
Holding
21
New
5
Increased
6
Reduced
1
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Palisade Bio
PALI
|
+$12.6M |
| 2 |
ADMA Biologics
ADMA
|
+$11.8M |
| 3 |
NRX Pharmaceuticals
NRXP
|
+$6.06M |
| 4 |
DRUG
Bright Minds Biosciences
DRUG
|
+$5.43M |
| 5 |
Structure Therapeutics
GPCR
|
+$2.57M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apogee Therapeutics
APGE
|
+$908K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
ADMA Biologics
ADMA
$2.02B
| $28.9M | 21.43% |
3,207,542
+750,000
| +31% | +$11.8M |
|
|
2
Palisade Bio
PALI
$342M
| $20M | 14.81% |
11,414,285
+6,914,285
| +154% | +$12.6M |
|
3
Praxis Precision Medicines
PRAX
$8.77B
| $10.7M | 7.94% |
33,237
| – | – |
|
|
CLLS
4
Cellectis
CLLS
$265M
| $10.4M | 7.71% |
3,281,501
| – | – |
|
5
Zai Lab
ZLAB
$2.28B
| $8.48M | 6.28% |
450,646
+50,646
| +13% | +$939K |
|
6
Taysha Gene Therapies
TSHA
$1.71B
| $8.05M | 5.97% |
1,800,556
| – | – |
|
|
7
NRX Pharmaceuticals
NRXP
$183M
| $6.39M | 4.74% |
+3,000,000
| New | +$6.06M |
|
|
8
Structure Therapeutics
GPCR
$3.45B
| $6.15M | 4.56% |
127,500
+37,500
| +42% | +$2.57M |
|
9
Iovance Biotherapeutics
IOVA
$2.23B
| $5.26M | 3.9% |
1,500,000
| – | – |
|
10
Spyre Therapeutics
SYRE
$8.7B
| $5.04M | 3.74% |
100,000
| – | – |
|
|
DRUG
11
Bright Minds Biosciences
DRUG
$747M
| $4.93M | 3.65% |
+67,500
| New | +$5.43M |
|
12
Assembly Biosciences
ASMB
$531M
| $4.88M | 3.61% |
175,706
| – | – |
|
13
Aura Biosciences
AURA
$723M
| $4M | 2.96% |
597,576
+25,000
| +4% | +$143K |
|
|
ORKA
14
Oruka Therapeutics
ORKA
$5.59B
| $3.68M | 2.73% |
75,000
| – | – |
|
15
Sight Sciences
SGHT
$274M
| $3.66M | 2.71% |
970,000
+50,000
| +5% | +$270K |
|
16
Ultragenyx Pharmaceutical
RARE
$2.88B
| $2.83M | 2.1% |
135,000
| – | – |
|
|
17
Apogee Therapeutics
APGE
$10.1B
| $631K | 0.47% |
7,500
-12,500
| -63% | -$908K |
|
18
Foghorn Therapeutics
FHTX
$305M
| $488K | 0.36% |
+102,000
| New | +$560K |
|
|
SLNO
19
DELISTED
Soleno Therapeutics
SLNO
| $251K | 0.19% |
+7,500
| New | +$294K |
|
20
Replimune Group
REPL
$859M
| $199K | 0.15% |
+26,000
| New | +$199K |
|
|
21
CALL
Replimune Group
REPL
$859M
| – | – |
-50,000
| Closed | -$486K |
|
Similar funds
UOP
ICM
EC
AV
FA
GEH
SA
SCM
B Group Inc's Q1 2026 Portfolio in Review
As of Q1 2026, B Group Inc held 21 positions worth $135M, down 0.4% from $135M the previous quarter. Its ten largest holdings account for 81% of the portfolio.
B Group Inc deployed $39.5M of net new capital in Q1 2026, opening 5 new positions and adding to 6 existing holdings. Its largest new stake was NRX Pharmaceuticals: 3,000,000 shares worth $6.39M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.
On the sell side, the largest reduction was Apogee Therapeutics, an estimated $908K trimmed.
- B Group Inc's largest Q1 2026 buy was NRX Pharmaceuticals: 3,000,000 shares worth $6.39M.
- B Group Inc added most to Palisade Bio in Q1 2026, an estimated $12.6M increase.
- B Group Inc's biggest Q1 2026 reduction was Apogee Therapeutics, cutting an estimated $908K.
- B Group Inc's ten largest holdings make up 81% of its $135M portfolio in Q1 2026.
- B Group Inc opened 5 new positions and closed 1 in Q1 2026.
- B Group Inc's portfolio value fell 0.4% quarter-over-quarter to $135M.
Based on B Group Inc's 13F filing for Q1 2026, filed 15 May 2026.